A few weeks ago, while reading the MedPlus Q3 FY25 earnings call transcript, one paragraph about the generics medicine stood out to us. What it basically said that the company’s private‑label generics are manufactured by the same WHO‑GMP plants that supply leading branded drugs but the consumer simply pays ~50-60% less.
That single remark set off a chain of questions. If large contract‑manufacturing organisations (CMOs) like Windlas can churn out both the ₹180 branded Telmisartan strip and a ₹25 private‑label equivalent, why does the branded product still dominate the chemist’s shelf (refer to image below) and is this shelf up for disruption?
The above data set us off on a deeper dive. We began mapping the broad structure of the Indian pharma landscape, trying to understand the balance between branded generics and trade generics. Along the way, we went through MedPlus earnings calls, not just to decode their strategy, but to zoom out and see what’s happening globally.
From Medplus, we figured that in US 90% of medicines sold are unbranded generics (snapshot below).
This led us to a compelling hypothesis: perhaps the Indian pharma retail market is standing at the cusp of disruption. A quiet but decisive shift from branded generics to trade generics may be underway, driven by pricing pressures, evolving consumer awareness, and changing regulatory moods. With this, we started looking for the pure play generics retailer and came across Zota Healthcare and its wholly‑owned subsidiary Davaindia, a 1582‑store chain where every single SKU is a private‑label generic.
In this note, we will walk you through:
The structural shift powering unbranded generics: policy nudges, doctor behaviour, and household budgets.
Dava India Model at the unit level
Management’s strategic pivots and learnings since 2017 and why they matter.
Present and future financials, Valuation scenarios & recommendation (reserved for our clients)
Conclusive thoughts
STRUCTURAL SHIFT TOWARDS GENERICS
India’s shift toward generic medicines is accelerating, driven by three converging forces. First, government policy is strongly pushing generic adoption, with the ambitious Pradhan Mantri Jan Aushadhi program targeting expansion to 25000 stores by FY26. Simultaneously, new NMC guidelines are nudging doctors to prescribe molecules over brands, reinforcing consumer comfort with generics.
Second, the powerful economic incentive is clear: medications represent ~70% of India's substantial out-of-pocket healthcare spending, and generic drugs can offer significant savings. As mentioned above, generic medicines being 80-90% cheaper than branded can significantly add to the savings for the end user.
Third, quality parity has become undeniable. Leading CMOs like Windlas and Akums, with WHO-GMP and USFDA certifications, now produce generics identical in quality to branded counterparts, dissolving the perception that cheaper means unsafe.
The shift is amplified by consumers becoming digitally savvy post-COVID, patients increasingly research molecule names and prices online before buying. Doctors, especially in rural areas, are now prescribing molecules (e.g., “AMOX 500 mg”) rather than brands (e.g., Moxclav™). Together, these changes mark a fundamental move toward an empowered, cost-conscious consumer in Indian healthcare.
INTRODUCTION TO ZOTA HEALTHARE LTD (DAVA INDIA):
Zota Health Care began its journey in 2000 as a pharmaceutical formulations trading company based in Surat. For years, the company steadily expanded its distribution footprint, becoming a reliable partner for numerous branded formulations manufacturers. However, by around 2016, the company's management sensed a fundamental shift emerging in India's pharmaceutical landscape. The generics segment, historically overshadowed by branded medicines, was beginning to gain momentum driven by rising healthcare costs, government policy support, and growing consumer awareness about medicine affordability and quality parity.
Recognizing this tectonic shift as both a challenge and a significant opportunity, Zota’s promoters decided to pivot strategically. Instead of merely supplying formulations, they realized that controlling the retail interface, where margins, customer loyalty, and brand trust are captured, would be critical. In 2017, Zota launched its fully owned subsidiary, Davaindia Health Mart, as a retail pharmacy chain focused exclusively on high-quality, unbranded generic medicines.
In less than a decade, Davaindia has grown dramatically, becoming India's largest dedicated generics pharmacy chain. As of Q3 FY25, Davaindia operates an expansive network of 1,582 stores across the country. These stores are structured into two formats:
852 COCO (Company-Owned, Company-Operated) stores, fully controlled by Davaindia, ensuring uniform brand experience, stringent quality assurance, and centralized supply-chain management.
730 FOFO (Franchisee-Owned, Franchisee-Operated) stores, providing rapid scale through asset-light expansion and deeper market penetration without heavy upfront capital commitments from Zota.
Davaindia stores includes over 2,212 SKUs, each meticulously selected and manufactured by leading tier-1 pharmaceutical CMOs like Windlas Healthcare and Akums Drugs. These CMOs hold stringent international quality certifications, such as WHO-GMP and USFDA approvals, ensuring each product maintains exacting global quality standards, identical to their branded counterparts.
In this note, we will specifically focus on Dava India and ignore the other business which we think are not so important in the overall scheme of things. Zota’s management has consciously directed every incremental rupee of capital, strategic bandwidth, and investor disclosure towards growing Davaindia.
One thing which we really like about Zota Healthcare is that Dava India, the subsidiary remains 100% owned by Zota Health Care, ensuring that any success directly translates into value creation for minority shareholders without dilution through external funding at the subsidiary level. Even the latest funding happened at the parent Zota healthcare level which was channeled into Dava India thereby ensuring 100% stake being held by Zota.
BUSINESS MODEL AND ECONOMICS
Davaindia’s entire business proposition rests on a clear and disruptive premise: eliminating multiple layers of intermediaries in the traditional pharmaceutical supply chain and passing significant cost benefits directly to consumers.
In the traditional pharma supply chain, a medicine travels from the manufacturer to a pharma marketing company, then onward through distributors and retailers before reaching the consumer. Each stage adds costs, including substantial marketing expenditures, distribution margins, and retail mark-ups, significantly inflating the final consumer price.
In sharp contrast, the Davaindia model radically simplifies this supply chain by sourcing directly from top-tier pharmaceutical manufacturers (CMOs like Windlas and Akums), bypassing all intermediaries. Medicines go directly from the manufacturer to Davaindia’s own pharmacy stores and then straight to consumers. By removing intermediaries such as pharma marketing companies, distributors, and third-party retailers, Davaindia drastically reduces costs and complexity (refer to snapshot below):
To illustrate how this works, consider the typical pricing structure in traditional pharmaceuticals: For a medicine priced at ₹100, the manufacturing cost might be just ₹10. Yet the remaining ₹90 is divided among marketing expenses (₹30), a pharma marketing company's margin (₹30), distributor margins (₹10), and retailer margins (₹20). Under Davaindia's streamlined model, that same medicine still manufactured at ₹10 has significantly lower additional costs. By cutting out distributor and third-party retailer margins entirely, and drastically reducing marketing expenditure, Davaindia can offer the medicine at around ₹25, a striking 75% discount compared to traditional branded medicines.
For example, consider the case of Rosuvastatin 10 mg tablets:
Branded generic from Sun Pharma retails at ₹208 for 10 tablets, with pharma companies capturing a large share of margins.
A trade generic from Cadila retails at ₹115.
However, the same generic molecule sold by Davaindia is priced at only ₹21, highlighting the dramatic price differential achievable through Davaindia’s simplified distribution model.
Competitiveness with other generic players
While India’s generic pharmacy landscape is seeing increased competition from players like Jan Aushadhi, Medkart, and Zeno, Davaindia clearly stands out on both product breadth and pricing strategy, as seen in the comparison below:
It is important at this point to cover Jan Aushadhi program of Gov of India and Dava India stacks against it.
Compared to the government’s Jan Aushadhi stores, Davaindia matches or surpasses price competitiveness while maintaining superior quality through reputed manufacturers. Its retail experience, featuring professional service and extensive product variety (over 1,700 SKUs), positions Davaindia as a premium yet affordable generics alternative. Further, due to Gov tendering process, there is limited control on Jan Aushadhi quality and efficacy which makes Davaindia even a better proposition.
Business Structure
Zota Health Care operates through a transparent corporate structure. The listed entity, Zota Health Care Limited, handles procurement of pharmaceutical products at arm’s length pricing (ALP) from third-party manufacturers.
Davaindia operates through a dual-store model: FOFO (Franchisee-Owned, Franchisee-Operated) and COCO (Company-Owned, Company-Operated) each serving a distinct strategic purpose. The FOFO model enables rapid expansion with minimal capital outlay by leveraging local entrepreneurs, making it ideal for penetrating smaller towns and new geographies. These stores are run by franchisees but supplied directly by the company, allowing Zota to maintain control over product quality and pricing. On the other hand, COCO stores are fully owned and operated by Davaindia, giving the company end-to-end control over the consumer experience, branding, store operations, and margins. This model also serves as a testbed for new products, store formats, and digital initiatives. Together, the FOFO and COCO formats provide Davaindia with a scalable, capital-efficient, and flexible retail strategy that balances growth with profitability and operational discipline.
Unit economics of COCO Stores
COCO stores form the backbone of its high-margin retail strategy. These walk-in pharmacies are fully owned and operated by the company, allowing complete control over pricing, branding, and customer experience. A matured COCO store generates approximately ₹6.4 lakh in monthly GMV, delivering ₹1.86 lakh in EBITDA at a 33% margin, driven by strong gross margins (~60%) and efficient cost structures. The store format is compact (400–500 sq. ft.), rent-efficient, and built for scalability with a short setup cycle of just 45–75 days.
New COCO stores follow a robust ramp-up curve. From ₹76,000 in GMV in the first month to ₹2.4 lakh by month ten. Currently, over a third of COCO stores are under 3 months old, offering strong embedded growth potential.
As per the company, the store sales reach 2.19x in the 15th month of COCO store Vs the first 3 month. Company also mentions that a matured store typically does a net revenue of 5.6 lacs per month (refer to the images below):
Our Workings on COCO
In our analysis, we assumed company to achieve a matured store sales level in the third year (or 25th Month) and we reverse calculated the first-year monthly sales. As shown below, the COCO stores hits break-even in the second year itself while generates an EBITDA of 22 lacs in the third year on a full year basis (on an average) with the starting capex of 12 -13 lacs. This is an extremely healthy economics.
Further, the company has standardised and made a comprehensive repeatable process towards opening its coco stores as shown below. Company has highly aggressive plans to opening 1000 COCO stores in the next 12 months and it has recently raised funds for the same.
Unit economics of FOFO Stores
In the FOFO store model, the franchisee partner does the capex and takes care of the rent and other operating expenses. Here the company supplies medicines to the FOFO store and records revenue after taking out the margin that it pays to the franchisee partner (26% of revenue is paid to FOFO partner). Hence, while in COCO company makes 60% GP, in case of FOFO company makes 46% GP. However there is no cost below GP (except the corporate overheads etc) which makes it a compelling business case:
Economics for Franchise partner
For the longevity of FOFO model, it is important for the Franchisee partner also to make money, with the help of company presentations, we tried to arrive at the franchisee partner level economics:
FAVORABLE STORE FUNDAMENTALS AND SSSG PERSPECTIVE
Few other details at the store level as shown below. There is a healthy percentage of revenue coming from chronic medicines as shown below:
Further, repeat customers make up 80% of sales thereby ensuring strong Life Time Value of a customer (LTV).
Same Store Sales Growth (SSSG): SSSG is a critical metric in evaluating the underlying health and operating leverage of any retail network, as it isolates performance from the noise of new store additions and reflects genuine consumer traction at existing locations. In the case of Davaindia, the company demonstrates robust SSSG across all store age brackets as shown below:
OPTIONALITIES
A few optionalities as shared by the company and as per our understanding:
Hyper‑Local E‑Pharmacy
A beta Android app already covers 1700 pincodes via its COCO stores. As COCO stores expected to increase rapidly, the penetration of this will increase proportionately generating even better economics at the store level (Think about Dominos Pizza).Vendor Bargaining Power
As volumes scale, Zota can negotiate net‑net prices, pushing gross margin >60 %. CMOs value consistent runs over one‑off branded batches.OTC Back‑Integration
The 56 % stake in Everyday Herbal (Khadi‑licensed gabion of balms, syrups) allows Zota to move up the brand curve where margins are fatter and price competition lower.
MANAGEMENT MISTAKES, OVERPROMISE AND LEARNING CURVE
While going through all the annual reports and presentations, we realised at various times that management has pivoted and also noted instances where they guided but fall short of achieving this. We think it is prudent to make a note of these events and keeping in mind before trusting any management guidance.
Instances of overpromise and under delivery:
In Q1 FY24 - company promised to open stores in 30 days (for Q2 FY24) from then 60 days, while as per latest ppt they are still taking 75 days (more than Q1 FY24 levels).
Target given in Q1 FY 24: Aspire to increase the FOFO store count from a current 493 stores to 993 stores by FY24 and COCO store count from current 101 to 351 by FY24. Actual: COCO as on FY24 end: 253. FOFO as on FY24 end: 627
Further article is reserved for our clients where we capture:
Current and future financials
Valuation scenarios, investment recommendation, Upside
Interaction with the company, pending questions
Risks, Corporate Governance checks
Response to any queries on Dava India
If you are interested in accessing our research and joining a network of well-informed investors, please contact us at Gaurav.a@nineonecapital.in
Disclaimer
This note presents an analytical overview of Zota Health Care Ltd. with a specific focus on its wholly owned retail subsidiary, Davaindia Health Mart Ltd. Our analysis is based entirely on publicly available information, including investor presentations, regulatory filings, company transcripts, and third-party research reports. We have not conducted any physical visits to company stores or facilities, and our observations rely solely on disclosures made by the company and data provided in official documents.
While the note includes a framework for understanding the business model and potential valuation scenarios, it does not constitute a buy or sell recommendation. Readers are encouraged to interpret this note as a tool for deeper understanding, not a substitute for personalized investment advice. We strongly advise investors to consult their SEBI-registered investment advisor before making any financial decisions based on this content.
Why did they pivot from FOFO to COCO ? Did the FOFO model fail ?
I have visited so many stores in Bombay and even their manufacturing facility in Surat. Business looks interesting to me but they are fighting to become profitable. While the stock is going sky high valuations.